Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial
Hannelore Ehrenreich(Max Planck Institute of Experimental Medicine), Anna‐Leena Sirén(University of Würzburg), Anthony Cerami(Araim Pharmaceuticals (United States)), Lukas Cepek(Max Planck Society), Michael Brines(Northwell Health), Michael Stiefel(University of Göttingen), Olaf Gefeller(Friedrich-Alexander-Universität Erlangen-Nürnberg), Sonja Jacob(Max Planck Society), W. Poser(Max Planck Society), Piotr Lewczuk(Universitätsklinikum Erlangen), Thomas Wessel(Janssen (United States)), Loretta M. Itri(National Institutes of Health), Christoph Dembowski(Max Planck Society), Marc De Ryck(Janssen (Belgium)), N Breiter(University of Göttingen), Eckart Rüther(Max Planck Society), Matthias Bohn(University of Göttingen), Hans-Heino Rustenbeck(University of Göttingen), Hilmar Prange, Christoph H. Gleiter(University of Tübingen), Friederike Knerlich‐Lukoschus(Max Planck Society), Michael M. Kochen(University of Freiburg), Martin Hasselblatt(University Hospital Münster)
Cited by 1,030
Related Papers
Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury
|Proceedings of the National Academy of Sciences|2000|1.4k
Prevention of Second Primary Tumors with Isotretinoin in Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|1990|1.4k
Impact of Cancer-Related Fatigue on the Lives of Patients: New Findings From the Fatigue Coalition
|The Oncologist|2000|1.3k
Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress
|Proceedings of the National Academy of Sciences|2001|1k